This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mohr, D. C Articles by Bedell, L. Search for Related Content PubMed PubMed Citation Articles by Mohr, D. C Articles by Bedell, L. Social Bookmarking                         What's this?

Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis

UCSF/Mt.Zion MS Center, 1701 Divisadero St., San Francisco, CA, 94115-1642, USA

Donald E Goodkin

UCSF/Mt.Zion MS Center, 1701 Divisadero St., San Francisco, CA, 94115-1642, USA

Lorianne Masuoka

Berlex Laboratories, 15049 San Pablo Ave., Richmond, California, CA 94804, USA

Leah P Dick

UCSF/Mt.Zion MS Center, 1701 Divisadero St., San Francisco, CA, 94115-1642, USA

David Russo

UCSF/Mt.Zion MS Center, 1701 Divisadero St., San Francisco, CA, 94115-1642, USA

Jannelle Eckhardt

UCSF/Mt.Zion MS Center, 1701 Divisadero St., San Francisco, CA, 94115-1642, USA

Arne C Boudewyn

Berlex Laboratories, 15049 San Pablo Ave., Richmond, California, CA 94804, USA

Lisa Bedell

Berlex Laboratories, 15049 San Pablo Ave., Richmond, California, CA 94804, USA

The purpose of this study was to examine the relationship between patient management strategies employed by study personnel, and patient retention and adherence to treatment in the first year of a Phase III clinical trial of interferon beta-1b for treatment of secondary progressive multiple sclerosis (MS). Study staff from each of 35 sites were interviewed regarding patient management practices. Sites which were rated as more empathetic, as instilling a sense of purpose in the patient, and promoting less formal relationships with patients had high rates of adherence to treatment. In addressing specific patient concerns, attention to patients' emotional status and patients' expectations of trial participation were related to better adherence.

Key Words: multiple sclerosis • clinical trials • adherence • compliance

Multiple Sclerosis, Vol. 5, No. 3, 192-197 (1999)
DOI: 10.1177/135245859900500309


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A.P. Turner, D.R. Kivlahan, A.P. Sloan, and J.K. Haselkorn Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model Multiple Sclerosis, November 1, 2007; 13(9): 1146 - 1152. [Abstract] [PDF]

				J. Rio, J. Porcel, N. Tellez, A. Sanchez-Betancourt, M a. Tintore, M J. Arevalo, C. Nos, and X. Montalban Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis Multiple Sclerosis, June 1, 2005; 11(3): 306 - 309. [Abstract] [PDF]